Metabolic intelligence for the decisions that don't have data yet
Imagine drug trials designed around real metabolic phenotypes. Insurance models that see trajectories, not snapshots. Prevention policy shaped by what actually moves outcomes. Training programs calibrated to each athlete's biology. Entire formats built on what bodies reveal in real time. Jul.ia makes this possible.
Not a health record.
A living metabolic model.
The Digital Phenotype is a multi-dimensional temporal model of how an individual's metabolism actually works: biomarkers, behaviors, exposures, clinical responses, and treatment outcomes — interacting and evolving over time.
It operates at individual resolution and aggregates at population scale. The result is the most granular metabolic intelligence available — structured to answer questions that no clinical trial, claims database, or wearable dataset can address.
The platform adapts to any data context: clinical records from hospital systems, real-time biometrics from athletes in competition, continuous monitoring from longitudinal care programs, or live physiological feeds from any environment where metabolic intelligence creates value.
What the platform makes possible
Three capabilities that no existing data source — clinical trials, claims databases, wearables, or EHRs — can produce today.
Real-World Cohort Discovery
Identify subpopulations by metabolic phenotype — not demographics or diagnosis codes. Find cohorts with specific biomarker trajectories, treatment histories, and response patterns that no existing registry can surface.
Metabolic Trajectory Forecasting
Model how individual or population-level metabolic health evolves over time. Identify intervention windows, predict risk shifts, and forecast outcomes at a resolution no actuarial or epidemiological model achieves.
Intervention-Outcome Intelligence
Map specific interventions — pharmacological, nutritional, behavioral, or environmental — to measurable outcomes across metabolic subpopulations. Individual-resolution evidence of what works, for whom, and under which conditions.
Where metabolic intelligence creates value
The same core platform, applied to fundamentally different problems across industries.
The real-world evidence that next-generation metabolic drugs require
Clinical trials establish efficacy under controlled conditions. They don’t reveal how a drug performs across the metabolic diversity of a real population — different comorbidities, different adherence patterns, different baseline physiologies.
For pharma teams developing GLP-1 agonists, SGLT2 inhibitors, and next-generation metabolic therapies, Jul.ia provides the real-world cohort and evidence infrastructure that accelerates every stage from trial design to post-market surveillance.
What makes Jul.ia different
Physician-validated, not self-reported
Intelligence grounded in clinical validation. Not patient guesses, not passive wearable captures. Physician decisions against structured ontologies — the quality standard that regulators and institutions require.
Longitudinal, not episodic
Claims databases capture visits. Jul.ia captures the trajectory between them. Continuous temporal depth on how metabolic profiles evolve and respond — the dimension that makes forecasting possible.
Individual resolution, not population averages
Epidemiological data describes populations. The Digital Phenotype describes individuals — and aggregates them into cohorts defined by metabolic reality, not demographic proxies.
Adaptive to any data context
The same intelligence platform operates on hospital EHR data, real-time athlete biometrics, longitudinal clinical records, or live physiological feeds from a production set. One engine, any input.
If your decisions depend on metabolic outcomes, this intelligence will matter
We're building the platform now. The partnerships that shape it will define what it becomes.